Johnson & Johnson (NYSE:JNJ) Position Maintained by Cornerstone Advisors Inc.

Cornerstone Advisors Inc. maintained its position in Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,598 shares of the company’s stock at the end of the first quarter. Johnson & Johnson accounts for about 0.9% of Cornerstone Advisors Inc.’s portfolio, making the stock its 12th largest position. Cornerstone Advisors Inc.’s holdings in Johnson & Johnson were worth $1,569,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Glenview State Bank Trust DEPT. boosted its position in shares of Johnson & Johnson by 0.5% in the first quarter. Glenview State Bank Trust DEPT. now owns 71,464 shares of the company’s stock valued at $8,901,000 after buying an additional 363 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Johnson & Johnson by 12.7% in the first quarter. Janney Montgomery Scott LLC now owns 768,335 shares of the company’s stock valued at $95,696,000 after buying an additional 86,458 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co boosted its position in shares of Johnson & Johnson by 1.5% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 69,707 shares of the company’s stock valued at $8,682,000 after buying an additional 1,007 shares in the last quarter. BTR Capital Management Inc. boosted its position in shares of Johnson & Johnson by 2.7% in the first quarter. BTR Capital Management Inc. now owns 99,020 shares of the company’s stock valued at $12,333,000 after buying an additional 2,626 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Johnson & Johnson by 1.2% in the first quarter. Fisher Asset Management LLC now owns 11,093,898 shares of the company’s stock valued at $1,381,745,000 after buying an additional 136,764 shares in the last quarter. 66.10% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (JNJ) traded down 0.31% during trading on Friday, reaching $132.63. 4,792,761 shares of the company were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The stock has a market capitalization of $355.98 billion, a price-to-earnings ratio of 22.44 and a beta of 0.78. The company has a 50 day moving average price of $132.88 and a 200-day moving average price of $127.04.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter last year, the firm posted $1.74 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.

COPYRIGHT VIOLATION NOTICE: This story was posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/cornerstone-advisors-inc-has-1569000-position-in-johnson-johnson-nysejnj-updated-updated-updated.html.

Several research analysts have recently weighed in on the stock. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday. J P Morgan Chase & Co lifted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $134.12.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply